Articles Tagged With: long-acting
-
Revamping the Daily Pill: Research to Begin on Monthly Pill
Although lowering side effects plays an important role in oral contraceptive compliance, one of the biggest challenges for patients is adhering to the daily schedule of the pill. Forgetting one to three pills per cycle is a frequent problem among 15-51% of users, particularly among adolescents. Lyndra Therapeutics has received a $13 million grant from the Bill & Melinda Gates Foundation and is setting out to remove the daily pill compliance challenge. The company is in early development of a monthly oral contraceptive to provide women with a discreet, noninvasive, reversible contraception option.
-
Researchers Investigate Microneedle Skin Patch Technology for Contraception Delivery
Researchers are studying microneedle skin patch technology for providing a long-acting contraceptive method that can be self-administered.
-
Long-Acting Reversible Contraception: Progress Made, but Challenges Remain
In 2002, just 2.4% of U.S. women using birth control were using long-acting reversible contraceptive (LARC) methods, such as the intrauterine device or the contraceptive implant. By 2014, about 14% of women using birth control reported LARC use.
-
Check Your Clinical Practice for LARC Methods
The American College of Obstetricians and Gynecologists now recognizes immediate postpartum placement of either the intrauterine device or the contraceptive implant as a best practice because of the long-acting reversible contraceptive methods’ role in preventing rapid repeat and unintended pregnancy
-
Training Can Help Integrate LARC Options Into Contraceptive Care
Research from the Bixby Center for Global Reproductive Health at the University of California, San Francisco, and Planned Parenthood Federation of America indicates that a four-hour training intervention can significantly affect the likelihood that healthcare providers will integrate long-acting reversible contraceptives into their clinical care.
-
Data Indicate Efficacy of Liletta IUD for Four Years’ Use
Four-year data from the ongoing multicenter, U.S.-based pivotal trial of the 52 mg Liletta levonorgestrel-releasing intrauterine device (IUD) indicate its safety and efficacy for four years of use in nulliparous and parous women, as well as in non-obese and obese women.
-
More Teens Using Contraception, Data Show
While more relying on IUDs and other methods, pill use remains common
-
FDA Approves IUS Contraceptive For Up to Five Years
The FDA approved Kyleena, a levonorgestrel-releasing, progestin-containing IUS, for up to five years.
-
What’s in the Pipeline? Science Moves Long-acting Contraceptive Options Forward
With the growth in interest in long-acting reversible contraceptive methods, what new options may be available to U.S. women?
-
Survey results show use of LARC continues to rise
About 46% of participants in the 2015 Contraceptive Technology Update Contraception Survey say they have seen “dramatically more” women choosing long-acting reversible contraceptive methods such as the intrauterine device and contraceptive implant in the last year.